Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2157299 plus sorafenib vs sorafenib in hepatocellular carcinoma
CTR20150343Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of galunisertib in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Started Jul 2015; status: active.
02
Drugs
galunisertib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20150343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150343.